Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Yusuf Ilhan; Ali Murat Tatli; Fatih Teker; Arif Hakan Onder; Fatih Kose; Caglayan Geredeli; Mustafa Karaagac; Muhammet Ali Kaplan; Mevlude Inanc; Sabin Goktas Aydin; Aysegul Kargi; Hacı Arak; Banu Ozturk; Ali Ayberk Besen; Oguzhan Selvi; Mustafa Korkmaz; Zeynep Oruc; Oktay Bozkurt; Ahmet Bilici; Selami Bayram; Shute Ailia Dae; Mustafa Ozdogan; Hasan Senol Coskun; Sema Sezgin Goksu

doi:10.1136/ijgc-2021-003165

Article info

other Versions

You are currently viewing an earlier version of this article (April 04, 2022).
View the most recent version of this article

Original research

Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Authors

Yusuf Ilhan Department of Medical Oncology, Akdeniz University, Antalya, Turkey PubMed articles Google scholar articles
Ali Murat Tatli Department of Medical Oncology, Akdeniz University, Antalya, Turkey PubMed articles Google scholar articles
Fatih Teker Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey PubMed articles Google scholar articles
Arif Hakan Onder Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey PubMed articles Google scholar articles
Fatih Kose Department of Medical Oncology, Başkent Üniversitesi Adana Uygulama ve Araştırma Merkezi, Adana, Turkey PubMed articles Google scholar articles
Caglayan Geredeli Department of Medical Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey PubMed articles Google scholar articles
Mustafa Karaagac Department of Clinical Oncology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, Turkey PubMed articles Google scholar articles
Muhammet Ali Kaplan Department of Medical Oncology, Dicle University, Diyarbakir, Turkey PubMed articles Google scholar articles
Mevlude Inanc Department of Medical Oncology, Erciyes University, Kayseri, Turkey PubMed articles Google scholar articles
Sabin Goktas Aydin Department of Medical Oncology, Istanbul Medipol University, Istanbul, Turkey PubMed articles Google scholar articles
Aysegul Kargi Department of Medical Oncology, Medstar Antalya Hospital, Antalya, Turkey PubMed articles Google scholar articles
Hacı Arak Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey PubMed articles Google scholar articles
Banu Ozturk Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey PubMed articles Google scholar articles
Ali Ayberk Besen Department of Medical Oncology, Başkent Üniversitesi Adana Uygulama ve Araştırma Merkezi, Adana, Turkey PubMed articles Google scholar articles
Oguzhan Selvi Department of Medical Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey PubMed articles Google scholar articles
Mustafa Korkmaz Department of Clinical Oncology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, Turkey PubMed articles Google scholar articles
Zeynep Oruc Department of Medical Oncology, Dicle University, Diyarbakir, Turkey PubMed articles Google scholar articles
Oktay Bozkurt Department of Medical Oncology, Erciyes University, Kayseri, Turkey PubMed articles Google scholar articles
Ahmet Bilici Department of Medical Oncology, Istanbul Medipol University, Istanbul, Turkey PubMed articles Google scholar articles
Selami Bayram Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey PubMed articles Google scholar articles
Shute Ailia Dae Department of Medical Oncology, Başkent Üniversitesi Adana Uygulama ve Araştırma Merkezi, Adana, Turkey PubMed articles Google scholar articles
Mustafa Ozdogan Department of Medical Oncology, Medstar Antalya Hospital, Antalya, Turkey PubMed articles Google scholar articles
Hasan Senol Coskun Department of Medical Oncology, Akdeniz University, Antalya, Turkey PubMed articles Google scholar articles
Sema Sezgin Goksu Department of Medical Oncology, Akdeniz University, Antalya, Turkey PubMed articles Google scholar articles

Correspondence to Dr Yusuf Ilhan, Department of Medical Oncology, Akdeniz University, Antalya, Turkey; dryusufilhan{at}gmail.com

View Full Text

Citation

Ilhan Y, Tatli AM, Teker F, et al

Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

International Journal of Gynecologic Cancer Published Online First: 27 January 2022. doi: 10.1136/ijgc-2021-003165

Publication history

Received October 4, 2021
Accepted January 13, 2022
First published January 27, 2022.

Article Versions

You are currently viewing a Previous version of this article (4 April 2022).
View the most recent version of this article

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

other Versions

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password